163 related articles for article (PubMed ID: 37686150)
1. Forced Hepatic Expression of NRF2 or NQO1 Impedes Hepatocyte Lipid Accumulation in a Lipodystrophy Mouse Model.
Wakabayashi N; Yagishita Y; Joshi T; Kensler TW
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686150
[TBL] [Abstract][Full Text] [Related]
2. NAD(P)H:quinone oxidoreductase 1 activity reduces hypertrophy in 3T3-L1 adipocytes.
Vomhof-DeKrey EE; Picklo MJ
Free Radic Biol Med; 2012 Aug; 53(4):690-700. PubMed ID: 22683604
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice.
Xu J; Kulkarni SR; Donepudi AC; More VR; Slitt AL
Diabetes; 2012 Dec; 61(12):3208-18. PubMed ID: 22936178
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet.
Zhang YK; Yeager RL; Tanaka Y; Klaassen CD
Toxicol Appl Pharmacol; 2010 Jun; 245(3):326-34. PubMed ID: 20350562
[TBL] [Abstract][Full Text] [Related]
5. Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance.
Gu L; Du Y; Chen J; Hasan MN; Clayton YD; Matye DJ; Friedman JE; Li T
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2320934121. PubMed ID: 38630726
[TBL] [Abstract][Full Text] [Related]
6. Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner.
Sano A; Kakazu E; Hamada S; Inoue J; Ninomiya M; Iwata T; Tsuruoka M; Sato K; Masamune A
Hepatology; 2021 Sep; 74(3):1271-1286. PubMed ID: 33724516
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice.
Chartoumpekis DV; Yagishita Y; Fazzari M; Palliyaguru DL; Rao UN; Zaravinos A; Khoo NK; Schopfer FJ; Weiss KR; Michalopoulos GK; Sipula I; O'Doherty RM; Kensler TW; Wakabayashi N
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515034
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen sulfide attenuates calcification of vascular smooth muscle cells via KEAP1/NRF2/NQO1 activation.
Aghagolzadeh P; Radpour R; Bachtler M; van Goor H; Smith ER; Lister A; Odermatt A; Feelisch M; Pasch A
Atherosclerosis; 2017 Oct; 265():78-86. PubMed ID: 28865326
[TBL] [Abstract][Full Text] [Related]
10. Dual Deletion of
Wakabayashi N; Yagishita Y; Joshi T; Kensler TW
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731931
[TBL] [Abstract][Full Text] [Related]
11.
Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
[TBL] [Abstract][Full Text] [Related]
12. Docosahexaenoic Acid Induces Expression of Heme Oxygenase-1 and NAD(P)H:quinone Oxidoreductase through Activation of Nrf2 in Human Mammary Epithelial Cells.
Bang HY; Park SA; Saeidi S; Na HK; Surh YJ
Molecules; 2017 Jun; 22(6):. PubMed ID: 28604588
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
14. Caffeic acid prevents acetaminophen-induced liver injury by activating the Keap1-Nrf2 antioxidative defense system.
Pang C; Zheng Z; Shi L; Sheng Y; Wei H; Wang Z; Ji L
Free Radic Biol Med; 2016 Feb; 91():236-46. PubMed ID: 26721592
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
[TBL] [Abstract][Full Text] [Related]
16. Apigenin prevents metabolic syndrome in high-fructose diet-fed mice by Keap1-Nrf2 pathway.
Yang M; Jiang ZH; Li CG; Zhu YJ; Li Z; Tang YZ; Ni CL
Biomed Pharmacother; 2018 Sep; 105():1283-1290. PubMed ID: 30021365
[TBL] [Abstract][Full Text] [Related]
17. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
[TBL] [Abstract][Full Text] [Related]
19. Liver expression of Nrf2-related genes in different liver diseases.
Cheng ML; Lu YF; Chen H; Shen ZY; Liu J
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):485-91. PubMed ID: 26459724
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
